ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
98
HLB U.S. subsidiary Immunomic gets FDA approval for IND application for Merkel cell cancer treatment
admin
2022.02.04
97
HLB completed the acquisition of FA, highly expected to turn into a surplus this year
admin
2022.01.04
96
HLB's acquisition of non-clinical CRO ‘Knotus’, Completed New Drug Development Value Chain
admin
2021.12.27
95
Nanocovax COVID-19 vaccine proven effective
admin
2021.12.20
94
RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022
admin
2021.12.18
93
Rivoceranib is designated as an orphan drug for liver cancer treatment by the FDA
admin
2021.11.08
92
HLB acquires in vitro diagnostic company
admin
2021.10.28
91
HLB transforming into prominent biopharma company
admin
2021.10.08
90
HLB Group to put Covid-19 vaccine distributor G-TreeBNT under its arms
admin
2021.09.14
89
HLB’s Chinese partner to present efficacy of rivoceranib at ESMO meeting
admin
2021.09.14
1
2
3
4
5
6
7
8
9
10
>
>>